Abstract:Importance Pulmonary arterial hypertension (PAH) is a subtype of pulmonary hypertension (PH), characterized by pulmonary arterial remodeling. The prevalence of PAH is approximately 10.6 cases per 1 million adults in the US. Untreated, PAH progresses to right heart failure and death. Observations Pulmonary hypertension is defined by a mean pulmonary artery pressure greater than 20 mm Hg and is classified into 5 clinical groups based on etiology, pathophysiology, and treatment. Pulmonary arterial hypertension is 1 of the 5 groups of PH and is hemodynamically defined by right heart catheterization demonstrating a mean pulmonary artery pressure greater than 20 mm Hg, a pulmonary artery wedge pressure of 15 mm Hg or lower, and a pulmonary vascular resistance of 3 Wood units or greater. Pulmonary arterial hypertension is further divided into subgroups based on underlying etiology, consisting of idiopathic PAH, heritable PAH, drug- and toxin-associated PAH, pulmonary veno-occlusive disease, PAH in long-term responders to calcium channel blockers, and persistent PH of the newborn, as well as PAH associated with other medical conditions including connective tissue disease, HIV, and congenital heart disease. Early presenting symptoms are nonspecific and typically consist of dyspnea on exertion and fatigue. Currently approved therapy for PAH consists of drugs that enhance the nitric oxide-cyclic guanosine monophosphate biological pathway (sildenafil, tadalafil, or riociguat), prostacyclin pathway agonists (epoprostenol or treprostinil), and endothelin pathway antagonists (bosentan and ambrisentan). With these PAH-specific therapies, 5-year survival has improved from 34% in 1991 to more than 60% in 2015. Current treatment consists of combination drug therapy that targets more than 1 biological pathway, such as the nitric oxide-cyclic guanosine monophosphate and endothelin pathways (eg, ambrisentan and tadalafil), and has shown demonstrable improvement in morbidity and mortality compared with the previous conventional single-pathway targeted monotherapy. Conclusions and Relevance Pulmonary arterial hypertension affects an estimated 10.6 per 1 million adults in the US and, without treatment, typically progresses to right heart failure and death. First-line therapy with drug combinations that target multiple biological pathways are associated with improved survival.

Introduction to guideline for diagnosis and treatment of pulmonary hypertension of European Respiratory Society and European Society of Cardiology on 2009 edition(partⅠ)

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

The interpretation of new hypertension guidelines

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Intensive reading and interpretation of Pediatric Advanced Life Support:2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation

[Guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (2024 edition)]

How Do We Respond to the Newly-Revised Haemodynamic Definitions of Pulmonary Hypertension

[Genetic diagnostics and molecular approaches in pulmonary arterial hypertension]

Diagnosis and evaluation of pulmonary hypertension

Recent Advances in the Diagnosis and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension

Advances in the Study of Inhaled Formulations for the Treatment of Pulmonary Arterial Hypertension

Strengthening the Construction of Standardized System to Enhance the Standard Diagnosis, Treatment and Comprehensive Management of Pulmonary Hypertension in China

Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.

Current diagnosis, pathogenesis and treatment of pulmonary hypertensive crisis

Review of current recommendations for diagnosis and treatment of patients with pulmonary hypertension

[Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension]

2005美国心脏学会心肺复苏与心血管急救指南(一)

Definition, classification and diagnosis of pulmonary hypertension

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases

Current Progression in Diagnosis and Treatment of Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease

Understanding of International Guidelines 2005 for Pediatric Cardiopulmonary Resuscitation:Advanced Life Support